Match!
Peter S. Sever
National Institutes of Health
EndocrinologyCardiologyDiabetes mellitusMedicineBlood pressure
508Publications
72H-index
30.1kCitations
What is this?
Publications 513
Newest
#1Baris Gencer (Geneva College)H-Index: 21
#2François Mach (Geneva College)H-Index: 61
Last. Narimon Honarpour (Amgen)H-Index: 17
view all 15 authors...
Importance The 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol identified patients with recent (past 12 months) myocardial infarction (MI) as very high risk, in whom a PCSK9 inhibitor is reasonable to add to maximally tolerated statin combined with ezetimibe if their low-density lipoprotein cholesterol level is 70 mg/dL or greater or non–high-density lipoprotein cholesterol level is 100 mg/dL or greater. Objective To ex...
Source
#1Nicholas Marston (Brigham and Women's Hospital)H-Index: 7
#2Yared Gurmu (Brigham and Women's Hospital)H-Index: 8
Last. Steven A. Lubitz (Broad Institute)H-Index: 49
view all 15 authors...
Background: The relationship between cholesterol levels and risk of venous thromboembolism (VTE) is uncertain. We set out to determine the effect of PCSK9 inhibition on the risk of VTE, explore pot...
Source
#1Peter S. Sever (NIH: National Institutes of Health)H-Index: 72
#2Sebastian L. Johnston (NIH: National Institutes of Health)H-Index: 87
Source
#1Stephen D. Wiviott (Brigham and Women's Hospital)H-Index: 72
#2Robert P. Giugliano (Brigham and Women's Hospital)H-Index: 71
Last. Christopher E. Kurtz (Amgen)H-Index: 10
view all 15 authors...
Importance: The PCSK9 inhibitor evolocumab reduced major vascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, yet the types and sizes of myocardial outcomes in FOURIER have not been previously explored. Objective: To assess the types and sizes of myocardial infarction (MI) and the effect of evolocumab on MI by subtype. Design, Setting, and Participants: A prespecified analysis of a multicenter double-blind randomize...
1 CitationsSource
#1Robert P. Giugliano (Brigham and Women's Hospital)H-Index: 71
#2Terje R. PedersenH-Index: 74
Last. Huei Wang (Amgen)H-Index: 8
view all 12 authors...
Background and Purpose monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5-1.2) mmol/L and significantly reduced major vascular events in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). Herein, we report the results of a prespecified analysis of cerebrovascular events in the overall trial population and in patients stratified by prior stroke. Methods- FOURIER was a randomized, doubl...
3 CitationsSource
Source
#1Nicholas MarstonH-Index: 7
Last. Armando Lira PinedaH-Index: 8
view all 15 authors...
Background: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisi...
#1Nicholas Marston (Brigham and Women's Hospital)H-Index: 7
#2Frederick K. Kamanu (Brigham and Women's Hospital)H-Index: 1
Last. Christian T. Ruff (Brigham and Women's Hospital)H-Index: 34
view all 15 authors...
Background: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisi...
8 CitationsSource
#1Peter S. Sever (NIH: National Institutes of Health)H-Index: 72
#2Ioanna Gouni-Berthold (University of Cologne)H-Index: 31
Last. Michelle L. O'Donoghue (Brigham and Women's Hospital)H-Index: 33
view all 10 authors...
AimsSome trials have reported diminished efficacy for statins in the elderly, and in women compared with men. We examined the efficacy and safety of evolocumab by patient age and sex in the FOURIER...
Source
#1Peter S. Sever (Imperial College London)H-Index: 72
Source
12345678910